MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)tm Study ? the first national CKD patient registry that captures both ...

Auquan, the market leader in generative AI for deep work in financial services, today announced its Risk Agent, the first and only AI agent that autonomously completes entire risk monitoring and ...

The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.